Hanall Biopharma Co., Ltd. (KRX:009420)
South Korea · Delayed Price · Currency is KRW 50,400
-7,500 (-12.95%)
Jun 8, 2026, 3:30 PM KST
Hanall Biopharma Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, Hanall Biopharma stock has a consensus rating of "Strong Buy" and an average price target of ₩90,000. The average 1-year stock price forecast is 78.57% higher than the current stock price, while the lowest is ₩70,000 (+38.89%) and the highest is ₩130,000 (+157.94%).
Price Target: ₩90,000 (+78.57%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Hanall Biopharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 2 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 4 | 6 | 6 |
Financial Forecast
Revenue This Year
171.68B
from 155.18B
Increased by 10.63%
Revenue Next Year
193.80B
from 171.68B
Increased by 12.89%
EPS This Year
-0.93
from -109.00
EPS Next Year
143.82
from -0.93
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is KRW.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 175.0B | ||
| Avg | 171.7B | ||
| Low | 168.0B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 12.8% | ||
| Avg | 10.6% | ||
| Low | 8.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | -0.93 | ||
| Low | - |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |